Gilead Sciences Inc. (GILD) News

Gilead Sciences Inc. (GILD): $89.03

1.13 (+1.29%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GILD to Watchlist
Sign Up

Industry: Biotech


Ranked

of 381

in industry

Filter GILD News Items

GILD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GILD News Highlights

  • GILD's 30 day story count now stands at 38.
  • Over the past 29 days, GILD's stories per day has been in a clear uptrend, growing by about 0.29 per 2 days.
  • The most mentioned tickers in articles about GILD are ARC, DRUG and NICE.

Latest GILD News From Around the Web

Below are the latest news stories about GILEAD SCIENCES INC that investors may wish to consider to help them evaluate GILD as an investment opportunity.

Gilead (GILD), RCUS Announce Positive Data From NSCLC Study

Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).

Yahoo | November 29, 2022

Investors in Gilead Sciences (NASDAQ:GILD) have made a notable return of 46% over the past three years

Thanks in no small measure to Vanguard founder Jack Bogle, it's easy buy a low cost index fund, which should provide...

Yahoo | November 29, 2022

European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations

FOSTER CITY, Calif., November 29, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has authorized a new low-dose tablet dosage form of Biktarvy® (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) and an extension of the indication for Biktarvy to treat HIV infection in virologically suppressed children who are at least two years of age and weigh at least 14 kg. The European Marketing Authorization is the first pediatric approv

Yahoo | November 29, 2022

Overdone Selloff? Fed Talking Heads, Trading Gilead, Iger's Magic Disney Words

What happened on Monday, was largely profit-taking, pin action related to a couple of large names, and defensive selling.

Yahoo | November 29, 2022

Uncertainty Grips Markets, On A Clear Day Maybe You Can See A Week Ahead

Healthcare stocks are now favored by many strategists because of their defensive nature and focus on US markets.

TalkMarkets.com | November 28, 2022

Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges

Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher.

Yahoo | November 28, 2022

Gilead-Arcus Biosciences Partnered Lung Cancer Therapy Shows Continuous Positive Efficacy Measures

Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences (NASDAQ: RCUS) announced an update from the fourth interim analysis of Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. ARC-7 is evaluating the combinations of anti-TIGIT antibody domvanalimab plus zimberelimab (doublet) and domvanalimab plus zimberelimab and

Yahoo | November 28, 2022

Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer

FOSTER CITY, Calif. & HAYWARD, Calif., November 28, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. ARC-7 is evaluating the combinations of a

Yahoo | November 28, 2022

Retirement Stock Portfolio: 11 Safe Tech Stocks to Consider

In this article, we discuss the 11 safe tech stocks for a retirement stock portfolio. If you want to read about some more tech stocks, go directly to Retirement Stock Portfolio: 5 Safe Tech Stocks to Consider. There is broad-based consensus among finance professionals that the traditional definitions of growth and value stocks do hold-up […]

Yahoo | November 28, 2022

Retirement Stock Portfolio: 11 Safe Dividend Stocks to Consider

In this article, we discuss the 11 safe dividend stocks for a retirement stock portfolio. If you want to read about some more dividend stocks, go directly to Retirement Stock Portfolio: 5 Safe Dividend Stocks to Consider. Across the world, investors have been scrambling to find ways to strengthen their portfolios and reduce risk as […]

Yahoo | November 28, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7503 seconds.